Arno, P. S., M. H. Davis. Forthcoming. Why don’t we enforce existing drug price controls? The unrecognized and unenforced reasonable pricing requirements imposed upon patients deriving in whole or in part from federally funded research. Tulane Law Review.
2.
Bozzette, S. A., S. H. Berry, N. D. Duan, M. R. Frankel, A. A. Leibowitz, D. Lefkowitz, C. A. Emmons, J. W. Senterfitt, M. L. Berk, S. C. Morton, and M. F. Shapiro. 1998. The care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. New England Journal of Medicine339 (26): 1897-1904.
3.
Centers for Disease Control and Prevention. 2000. CDC update: A glance at the HIV epidemic. Atlanta, GA: Centers for Disease Control and Prevention.
4.
Gold, M. R., J. E. Siegel, L. B. Russell, and M. C. Weinstein, eds. 1996. Cost-effectiveness in health and medicine. New York: Oxford University Press.
5.
Goldman, D. P., J. Bhattacharya, A. A. Leibowitz, G. F. Joyce, M. F. Shapiro, and S. A. Bozzette. 2001. The impact of state policy on the costs of HIV infection. Medical Care Research and Review58 (1): 31-54.
6.
Kahn, J. G., B. Hail, J. Kates, and S. Chang. Forthcoming. The health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. American Journal of Public Health.
7.
Kaiser Family Foundation. 2000. Federal HIV/AIDS spending: A budget chart book, fiscal year 2000. Menlo Park, CA: Kaiser Family Foundation.
8.
U.S. Department of Health and Human Services. 2000. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [Online]. Available: http://www.hivatis.org
9.
U.S. Government Accounting Office. 1998. HIV/AIDS drugs: Funding implications of new combination therapies for federal and state programs. GAO/HEHS-99-2. Washington, DC: Government Printing Office.
